Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.36 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.36 |
| ▸ | PIM1 | P11309 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25145595 | 0.89 | MGLL (0.43) | MGLLFPR2ENPP2ATXN2PIM1 | |
| SCHEMBL30409868 | 0.89 | MGLL (0.36) | MGLL | |
| SCHEMBL30410100 | 0.85 | MGLL (0.37) | MGLLSLC6A4 | |
| SCHEMBL30408532 | 0.84 | MGLL (0.47) | MGLL | |
| SCHEMBL30410167 | 0.83 | MGLL (0.41) | MGLLENPP2ATXN2PIM1SLC6A4 | |
| SCHEMBL31549744 | 0.81 | ENPP2 (0.37) | MGLLENPP2ATXN2SLC6A4FFAR4 | |
| SCHEMBL25146079 | 0.80 | FAAH (0.43) | FPR2ENPP2ATXN2 | |
| SCHEMBL23850001 | 0.80 | FFAR4 (0.40) | MGLLENPP2ATXN2SLC6A4FFAR4 | |
| SCHEMBL25325656 | 0.78 | MGLL (0.44) | MGLLENPP2ATXN2SLC6A4FFAR4 | |
| SCHEMBL25145708 | 0.77 | MGLL (0.46) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4416154-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-08-21 | — | — | EP | claimed |
| CN-118103374-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | claimed |
| WO-2023062049-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-20 | — | — | WO | claimed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4416154-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-08-21 | — | — | EP | disclosed |
| CN-118103374-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023062049-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | MGLL 5/4885FPR2 3946/4885ENPP2 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.